SynthesisJournal of cardiothoracic surgery2025
Prognostic value of baseline glucose levels for mortality in patients with cardiogenic shock: a systematic review and meta-analysis.
Synthesis in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Characteristics and Outcomes of Patients Admitted in Cardiac Intensive Care Unit with Cardiogenic Shock: A Single-Center Study.Diseases (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBaseline glucose levels have been implicated in the prognosis of critically ill patients. However, the prognostic value of glucose in patients with cardiogenic shock (CS) has not been systematically evaluated. The current study aimed to provide evidence that baseline glucose levels can predict mortality in patients with CS.
methodsPubMed, Scopus, Embase and Web of Science were searched from inception to July 31, 2024 for studies assessing mortality after CS based on different baseline glucose levels. Hyperglycemia was defined as a glucose level > 7.8-8 mmol/l. Data were synthesized using "Review Manager" (RevMan; version 5.3; The Cochrane Collaboration).
resultsA total of nine studies were included. Meta-analysis showed that patients with CS who had baseline glucose levels > 7.8-8 mmol/l had a significantly greater risk of early mortality as compared to those with glucose levels < 7.8-8 mmol/l [risk ratio (RR), 1.48; 95% confidence interval (CI), 1.24-1.77; I-squared (I
conclusionIn the present meta-analysis, the elevated risk of mortality was persistent with different glucose cut-offs, suggesting that glucose levels at admission can be useful for risk assessment in patients with CS. Further studies considering diabetes status and other important confounding factors are needed to obtain more evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.